The World Health Organization estimates that tuberculosis is causing nearly two million deaths annually, mostly in developing countries. Widespread administration of the current tuberculosis vaccine to newborns is not a reliable route for preventing the disease in adults, the population that drives the epidemic. Several new vaccine candidates are in development, and a few have entered clinical trials. However, the field faces formidable scientific and policy challenges. A collaborative approach to solving scientific, policy, and resource obstacles—as well as new partnerships among emerging economies and vaccine development organizations—will be critical to developing a new tuberculosis vaccine that could achieve its public health potential to save lives and reduce the burden of disease.
Barker, L.F.; Leadman, A.E.; Clagett, B. The Challenges Of Developing New Tuberculosis Vaccines. Health Affairs (2011) 30 (6) 1073-1079. [DOI: 10.1377/hlthaff.2011.0303]
The Challenges Of Developing New Tuberculosis Vaccines